The DOI matches its Crossref record; 56 of the 56 references it cites were found in a registry or an index.
Fumarates improve psoriasis and multiple sclerosis by inducing type II dendritic cells
Open accessAbstract
Fumarates improve multiple sclerosis (MS) and psoriasis, two diseases in which both IL-12 and IL-23 promote pathogenic T helper (Th) cell differentiation. However, both diseases show opposing responses to most established therapies. First, we show in humans that fumarate treatment induces IL-4–producing Th2 cells in vivo and generates type II dendritic cells (DCs) that produce IL-10 instead of IL-12 and IL-23. In mice, fumarates also generate type II DCs that induce IL-4–producing Th2 cells in vitro and in vivo and protect mice from experimental autoimmune encephalomyelitis. Type II DCs result from fumarate-induced glutathione (GSH) depletion, followed by increased hemoxygenase-1 (HO-1) expression and impaired STAT1 phosphorylation. Induced HO-1 is cleaved, whereupon the N-terminal fragment of HO-1 translocates into the nucleus and interacts with AP-1 and NF-κB sites of the IL-23p19 promoter. This interaction prevents IL-23p19 transcription without affecting IL-12p35, whereas STAT1 inactivation prevents IL-12p35 transcription without affecting IL-23p19. As a consequence, GSH depletion by small molecules such as fumarates induces type II DCs in mice and in humans that ameliorate inflammatory autoimmune diseases. This therapeutic approach improves Th1- and Th17-mediated autoimmune diseases such as psoriasis and MS by interfering with IL-12 and IL-23 production.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Randomized, Placebo-Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis
Polman, C. H., O'Connor, P. W., Havrdova, E., Hutchinson, M., Kappos, L., Miller, D. H., Phillips, J. T., Lublin, F. D., Giovannoni, G., Wajgt, A., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa044397 · Cited by 3,386
Lutz, M. B., Kukutsch, N., Ogilvie, A. L. J., Rößner, S., Koch, F., Romani, N., & Schuler, G. (1999) · Journal of Immunological Methods · doi:10.1016/s0022-1759(98)00204-x · Cited by 2,966
Nestle, F. O., Kaplan, D. H., & Barker, J. (2009) · New England Journal of Medicine · doi:10.1056/nejmra0804595 · Cited by 2,786
Multiple Sclerosis — The Plaque and Its Pathogenesis
Frohman, E. M., Racke, M. K., & Raine, C. S. (2006) · New England Journal of Medicine · doi:10.1056/nejmra052130 · Cited by 1,740
Self-citationDifferential Antigen Processing by Dendritic Cell Subsets in Vivo
Dudziak, D., Kamphorst, A. O., Heidkamp, G. F., Buchholz, V. R., Trumpfheller, C., Yamazaki, S., Cheong, C., Liu, K., Lee, H.-W., Park, C. G., et al. (2007) · Science · doi:10.1126/science.1136080 · Cited by 1,455
Dendritic-cell control of pathogen-driven T-cell polarization
Kapsenberg, M. L. (2003) · Nature Reviews Immunology · doi:10.1038/nri1246 · Cited by 1,437
Genome-wide scan reveals association of psoriasis with IL-23 and NF-κB pathways
for the Collaborative Association Study of Psoriasis, Nair, R. P., Duffin, K. C., Helms, C., Ding, J., Stuart, P. E., Goldgar, D., Gudjonsson, J. E., Li, Y., Tejasvi, T., et al. (2009) · Nature Genetics · doi:10.1038/ng.311 · Cited by 1,409
Association scan of 14,500 nonsynonymous SNPs in four diseases identifies autoimmunity variants
Wellcome Trust Case Control Consortium, & The Australo-Anglo-American Spondylitis Consortium (TASC) (2007) · Nature Genetics · doi:10.1038/ng.2007.17 · Cited by 1,374
Keyse, S. M., & Tyrrell, R. M. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.1.99 · Cited by 1,264
Napolitani, G., Rinaldi, A., Bertoni, F., Sallusto, F., & Lanzavecchia, A. (2005) · Nature Immunology · doi:10.1038/ni1223 · Cited by 1,157
Cited by
Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple Sclerosis
Gold, R., Kappos, L., Arnold, D. L., Bar-Or, A., Giovannoni, G., Selmaj, K., Tornatore, C., Sweetser, M. T., Yang, M., Sheikh, S. I., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1114287 · Cited by 1,733
Greb, J. E., Goldminz, A. M., Elder, J. T., Lebwohl, M. G., Gladman, D. D., Wu, J. J., Mehta, N. N., Finlay, A. Y., & Gottlieb, A. B. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.82 · Cited by 922
Sommermeyer, D., Hudecek, M., Kosasih, P. L., Gogishvili, T., Maloney, D. G., Turtle, C. J., & Riddell, S. R. (2016) · Leukemia · doi:10.1038/leu.2015.247 · Cited by 867
Therapeutics targeting the IL-23 and IL-17 pathway in psoriasis
Ghoreschi, K., Balato, A., Enerbäck, C., & Sabat, R. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00184-7 · Cited by 668
Self-citationTranscription Factor NRF2 as a Therapeutic Target for Chronic Diseases: A Systems Medicine Approach
Cuadrado, A., Manda, G., Hassan, A., Alcaraz, M. J., Barbas, C., Daiber, A., Ghezzi, P., León, R., López, M. G., Oliva, B., et al. (2018) · Pharmacological Reviews · doi:10.1124/pr.117.014753 · Cited by 632
Metadata
- Authors
- Ghoreschi, K., Brück, J., Kellerer, C., Deng, C., Peng, H., Rothfuss, O., Hussain, R. Z., Gocke, A. R., Respa, A., Glocova, I., Valtcheva, N., Alexander, E., Feil, S., Feil, R., Schulze-Osthoff, K., Rupec, R. A., Lovett-Racke, A. E., Dringen, R., Racke, M. K., & Röcken, M.
- Venue
- Journal of Experimental Medicine
- Publisher
- Rockefeller University Press
- Published
- 2011-10-10
- Volume
- 208
- Issue
- 11
- Pages
- 2291-2303
- ISSN
- 0022-1007 (ISSN-L)
- 1540-9538
- OpenAlex
- W2097593378
- Cited by
- 352
- References
- 56
- FWCI
- 12.39
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Fumarates improve psoriasis and multiple sclerosis by inducing type II dendritic cells. https://app.cochat.ai/papers/10.1084/jem.20100977
- The paper
- Ghoreschi, K., Brück, J., Kellerer, C., Deng, C., Peng, H., Rothfuss, O., Hussain, R. Z., Gocke, A. R., Respa, A., Glocova, I., Valtcheva, N., Alexander, E., Feil, S., Feil, R., Schulze-Osthoff, K., Rupec, R. A., Lovett-Racke, A. E., Dringen, R., Racke, M. K., & Röcken, M. (2011). Fumarates improve psoriasis and multiple sclerosis by inducing type II dendritic cells. Journal of Experimental Medicine. https://doi.org/10.1084/jem.20100977
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.